Your search
Results 5 resources
-
Preventing viral infections at an early stage is a key strategy of successfully improving transplant outcomes. Preemptive therapy and prophylaxis using antiviral agents have been used successfully to prevent clinically significant viral infections in hematopoietic cell transplant (HCT) recipients. Major progress has been made over the past decades in preventing viral infections through a better understanding of the biology and risk factors as well as the introduction of novel antiviral...
-
Cytomegalovirus (CMV) infection remains an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients. CMV cell-mediated immunity (CMV-CMI) as determined by a peptide-based enzyme-linked immunospot (ELISPOT) CMV assay may identify patients at risk for clinically significant CMV infection (CS-CMVi).The CS-CMVi was defined as CMV viremia and/or disease necessitating antiviral therapy. CMV-CMI was characterized as high when the...
-
CMV infection is a common complication in patients undergoing hematopoietic-cell transplantation. The incidence of CMV infection was 23 percentage points lower with prophylactic letermovir, a CMV–terminase complex inhibitor, than with placebo, with only low-level toxic effects.
Filter by our tag
GUIDELINES
- ASTCT Guidelines (1)
ORGANISMS
-
VIRUSES
-
CMV
- Cell-Mediated Immunity Assays (1)
- Clinical (1)
- Letermovir (2)
- Adenovirus (1)
- HHV-6 (1)
- Polyomaviruses (1)
- VZV (1)
-
CMV
HEME-ONC AND CELLULAR THERAPIES
- BMT Guidelines (1)
- BMT-specific ID (1)
- Heme-onc prophylaxis (1)
- PTLD (1)